GENNIEFY
Market News
Latest financial news and analysis from global markets
KO
AI Stocks Are at Nosebleed Levels. Walmart, Exxon, and 7 More Oldies but Goodies.
The Nasdaq keeps hitting record highs. It’s time to take a look at something besides chips, AI, and software. Here are nine companies to consider.
BAC
Unemployment Among College Grads Still Dismal
Americans who recently earned their bachelor’s degree have faced a challenging job market in recent years.
XAU/USD
Analysts Expect Hemlo Mining Corp. (CVE:HMMC) To Breakeven Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Hemlo Mining Corp.'s...
PLD
Is Prologis (PLD) One of the Best Digital Infrastructure REITs?
Prologis, Inc. (NYSE:PLD) is one of the Best Digital Infrastructure REITs to Buy According to Analysts. On April 28, RBC Capital raised its price target on Prologis to $148 from $135 and maintained a Sector Perform rating on the stock, according to a report by TheFly. RBC highlighted that Prologis delivered healthy Q1 results, adding […]
GOOGL
Why Nvidia Stock Popped 14% in April and Could Go Even Higher
Nvidia stock hit a new all-time high in April, as investors flooded back into AI stocks. There could be more to come.
GOOGL
Bill Ackman Said High‑Quality Stocks Are Stupidly Cheap. He’s Right.
It’s been a big end to April for Bill Ackman as his much-anticipated Pershing Square USA (NYSE:PSUS) went live on public markets. Of course, it was a tough slog out of the gate, but for investors interested in a hefty discount, now could be as good a time as any to bet on Ackman, a ... Bill Ackman Said High‑Quality Stocks Are Stupidly Cheap. He’s Right.
MSFT
Bill Ackman Said High‑Quality Stocks Are Stupidly Cheap. He’s Right.
It’s been a big end to April for Bill Ackman as his much-anticipated Pershing Square USA (NYSE:PSUS) went live on public markets. Of course, it was a tough slog out of the gate, but for investors interested in a hefty discount, now could be as good a time as any to bet on Ackman, a ... Bill Ackman Said High‑Quality Stocks Are Stupidly Cheap. He’s Right.
PLTR
Nasdaq Touches Intraday High, Heads for Record Close
The Nasdaq was cruising on Tuesday despite another round of software stock struggles. The Dow was up 306 points, or 0.6%. The Nasdaq’s gains were even more impressive when you consider the Roundhill Magnificent Seven ETF was flat and the iShares Expanded Tech-Software Sector ETF was down 0.8%.
PLTR
Palantir Sinks 7% Despite Q1 Crusher: Sector Strength Exposes the Sky-High Valuation
Shares of Palantir Technologies (NASDAQ:PLTR) are down 7% in midday trading Tuesday, changing hands near $136 after the company delivered a blowout Q1 2026 earnings report and raised full-year guidance overnight. The selloff comes despite a clear beat-and-raise quarter. The move puts Palantir stock 23% lower year to date and well below its 52-week high ... Palantir Sinks 7% Despite Q1 Crusher: Sector Strength Exposes the Sky-High Valuation
MSFT
Palantir Sinks 7% Despite Q1 Crusher: Sector Strength Exposes the Sky-High Valuation
Shares of Palantir Technologies (NASDAQ:PLTR) are down 7% in midday trading Tuesday, changing hands near $136 after the company delivered a blowout Q1 2026 earnings report and raised full-year guidance overnight. The selloff comes despite a clear beat-and-raise quarter. The move puts Palantir stock 23% lower year to date and well below its 52-week high ... Palantir Sinks 7% Despite Q1 Crusher: Sector Strength Exposes the Sky-High Valuation
SNOW
Palantir Sinks 7% Despite Q1 Crusher: Sector Strength Exposes the Sky-High Valuation
Shares of Palantir Technologies (NASDAQ:PLTR) are down 7% in midday trading Tuesday, changing hands near $136 after the company delivered a blowout Q1 2026 earnings report and raised full-year guidance overnight. The selloff comes despite a clear beat-and-raise quarter. The move puts Palantir stock 23% lower year to date and well below its 52-week high ... Palantir Sinks 7% Despite Q1 Crusher: Sector Strength Exposes the Sky-High Valuation
PFE
Pfizer pins post 2028 return to growth on new obesity and cancer drugs
May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine. The New York-based drugmaker also beat Wall Street expectations for first-quarter revenue and profit, buoyed by strong demand for its blood thinner Eliquis and recently acquired products, as it faces looming patent expirations and fading COVID produ